Recruiting

Testing a new drug to prevent relapsed blood cancer from returning

Plain-English translation of NCT06947083 on ClinicalTrials.gov ↗ · Source last updated December 2025 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether , a newer medication, can help keep blood cancer from coming back in patients who have already been treated with a type of cell therapy called cilta-cel. The study focuses on patients whose cancer is considered higher-risk — meaning it has certain genetic features or has spread outside the bones. Researchers want to see if this medication can help prevent the cancer from progressing after the initial cell therapy treatment.

Some patients with high-risk blood cancer don't respond as well to the standard cell therapy treatment as others do, and their cancer can come back sooner. This trial is testing whether adding this medication afterward as a 'maintenance' treatment — like taking medicine to prevent relapse — can help keep the cancer under control longer.

Do you qualify?

You likely qualify if…

you have been diagnosed with relapsed blood cancer that has certain high-risk genetic features or has spread outside the bones
you have received cilta-cel cell therapy within the last 3 to 6 months and are showing no signs that your cancer is coming back
you have received at least 2 prior cancer treatment regimens before your cell therapy
you are in good enough overall health to tolerate the study treatment, as assessed by your doctor
you have a blood test available (clonoseq test) to monitor whether cancer cells remain in your blood during the study

You likely don't qualify if…

you currently have an active infection that is getting worse despite treatment
you are pregnant or breastfeeding
you have uncontrolled serious medical conditions such as heart disease, diabetes, or lung disease that your doctor believes make this trial too risky
you have a history of Guillain-Barré syndrome or active nervous system complications from your prior cell therapy
you are taking other cancer medications or treatments at the same time

What participation looks like

If you are eligible and join this trial, you will receive the medication as an infusion (IV) or injection starting 3 to 6 months after your cell therapy, and continue for 12 months total. You will need to come to the clinic regularly for visits to receive the medication, have blood tests done, and be monitored for any side effects. Your cancer will be tracked during this time to see how long you stay free from cancer progression.

AI-generated summary from trial data · Jul 15, 2026 · Not medical advice

Trial locations(1 site)

United States

Moffitt Cancer Center, Tampa, Florida